Clearside Biomedical (NASDAQ:CLSD – Get Free Report) and Phibro Animal Health (NASDAQ:PAHC – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.
Institutional & Insider Ownership
18.8% of Clearside Biomedical shares are owned by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are owned by institutional investors. 9.2% of Clearside Biomedical shares are owned by company insiders. Comparatively, 50.1% of Phibro Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Clearside Biomedical and Phibro Animal Health’s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Clearside Biomedical | $8.23 million | 10.62 | -$32.49 million | ($0.55) | -2.13 |
| Phibro Animal Health | $977.90 million | 0.78 | $32.61 million | $0.32 | 59.00 |
Volatility and Risk
Clearside Biomedical has a beta of 2.43, indicating that its stock price is 143% more volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500.
Profitability
This table compares Clearside Biomedical and Phibro Animal Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Clearside Biomedical | -413.73% | N/A | -94.66% |
| Phibro Animal Health | 1.32% | 17.11% | 4.83% |
Analyst Ratings
This is a summary of current recommendations for Clearside Biomedical and Phibro Animal Health, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Clearside Biomedical | 0 | 0 | 5 | 0 | 3.00 |
| Phibro Animal Health | 2 | 1 | 1 | 0 | 1.75 |
Clearside Biomedical currently has a consensus target price of $4.60, indicating a potential upside of 293.16%. Phibro Animal Health has a consensus target price of $14.75, indicating a potential downside of 21.88%. Given Clearside Biomedical’s stronger consensus rating and higher possible upside, analysts plainly believe Clearside Biomedical is more favorable than Phibro Animal Health.
Summary
Phibro Animal Health beats Clearside Biomedical on 9 of the 14 factors compared between the two stocks.
About Clearside Biomedical
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
About Phibro Animal Health
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, industrial, environmental, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.
